Table 1.
Baseline characteristics of patients before starting medication with a SGLT2 inhibitor
| Variable | Value |
|---|---|
| Number of patients | 27 Empagliflozin 18 (1 × 5 mg; 5 × 10 mg; 12 × 25 mg) Dapagliflozin 9 (1 × 5 mg; 8 × 10 mg) |
| Age (years) | 58 (52; 68) |
| Sex (male) | 12 (43%) |
| BMI (kg/m2) | 36.3 (32.6; 46.1) |
| Body weight (kg) | 101.9 (87.8; 128.6) |
| Blood pressure | |
| Systolic (mmHg) | 141 (129; 153) |
| Diastolic (mmHg) | 88 (76; 99) |
| Heart rate (1/min) | 78 (70; 88) |
| Antidiabetic medication | |
| Insulin | 20 (71.5%) |
| Metformin | 26 (92.9%) |
| DPP4 inhibitor | 12 (42.9%) |
| GLP1 agonist | 7 (25%) |
| Therapy with RAAS inhibitor | 25 (93%) |
| ACE inhibitor | 20 (74%) |
| Angiotensin II receptor antagonist | 5 (18%) |
| Statin therapy | 15 (56%) |
| HbA1c (%) | 9.1 (8.1; 10.9) |
| Creatinine (mg/dL) | 0.7 (0.6; 0.9) |
| Proteinuria (mg/g creatinine) | 124 (78; 185) |
| Hematocrit (%) | 42 (39; 44) |
| Uric acid (mg/dL) | 4.7 (4.3; 5.9) |
| Cholesterol (mg/dL) | 172 (160; 200) |
| HDL cholesterol (mg/dL) | 46 (37; 54) |
| LDL cholesterol (mg/dL) | 104 (92; 135) |
| Macrovascular complications: history of | |
| Coronary artery disease/myocardial infarction | 10 (37%) |
| Stroke | 2 (7%) |
| Peripheral artery disease | 1 (4%) |
| Microvascular complications: history of | |
| Diabetic retinopathy | 1 (4%) |
| Diabetic nephropathy | 8 (31%) |
| Diabetic neuropathy | 6 (23%) |
Values reported are n (%) for categorical variables and median (interquartile range) for continuous variables
RAAS renin–angiotensin–aldosterone system, ACE angiotensin converting enzyme, HDL high density lipoprotein, LDL low density lipoprotein